Ultra Low float Gem / Trading below Cash/ Phase 3 Data in 1H 2018 //$650 Million Potential for the Drug /Stock should be at $15 right now and sky is limit on positive phase 3 outcome = A MUST HAVE .GLTA
The laggard But what about my third pick, Celsion (Nasdaq: CLSN)? I recommended it at a price of $2.75 back in October, and it eventually fell below $2 this past winter. This just shows you the risk of putting a lot of money into just one …
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer …
Celsion stock does not offer a high quality setup at the moment. Price movement …
Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer …
Celsion's (CLSN) pipeline candidate, GEN1, controls ovarian cancer in all patients in the phase Ib study and achieves a historical improvement in progression free survival.